A-319
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 15, 2019 (NCT04056975)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E inhibitor
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06400537 | Phase 1 | Jul 20, 2024 | Huazhong University of Science and Technology, ITabMed Co., Ltd. |
| NCT04056975 | Phase 1 | Sep 15, 2019 | Chinese Academy of Medical Sciences, Generon (Shanghai) Corporation Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Generon (Shanghai) Corporation Ltd. | For profit | 1 | 1 | 1 | 2019 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2024 |
| ITabMed Co., Ltd. | For profit | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1